PT - JOURNAL ARTICLE AU - Lek, Angela AU - Wong, Brenda AU - Keeler, Allison AU - Blackwood, Meghan AU - Ma, Kaiyue AU - Huang, Shushu AU - Sylvia, Katelyn AU - Batista, Ana Rita AU - Artinian, Rebecca AU - Kokoski, Danielle AU - Parajuli, Shestruma AU - Putra, Juan AU - Carreon, Chrystalle Katte AU - Lidov, Hart AU - Woodman, Keryn AU - Pajusalu, Sander AU - Spinazzola, Janelle M. AU - Gallagher, Thomas AU - LaRovere, Joan AU - Baulderson, Diane AU - Black, Lauren AU - Sutton, Keith AU - Horgan, Richard AU - Lek, Monkol AU - Flotte, Terence TI - Unexpected Death of a Duchenne Muscular Dystrophy Patient in an N-of-1 Trial of rAAV9-delivered CRISPR-transactivator AID - 10.1101/2023.05.16.23289881 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.16.23289881 4099 - http://medrxiv.org/content/early/2023/05/18/2023.05.16.23289881.short 4100 - http://medrxiv.org/content/early/2023/05/18/2023.05.16.23289881.full AB - An N-of-1 trial was developed to deliver a dCas9-VP64 transgene designed to upregulate the cortical dystrophin as a custom therapy for a Duchenne muscular dystrophy (DMD) patient. After showing signs of mild cardiac dysfunction and pericardial effusion, the patient acutely decompensated and sustained cardiac arrest six-days after dosing and succumbed two-days later. Post-mortem examination revealed severe acute-respiratory distress syndrome with diffuse alveolar damage. Vector biodistribution data was obtained and revealed minimal expression of transgene in liver. There was no evidence of AAV9 antibodies nor of effector T cell reactivity. These findings demonstrate innate immune signaling with capillary leak as a form of toxicity in an advanced DMD case treated with high-dose rAAV gene therapy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIND28497 NCT05514249Funding StatementThis study was funded by the 501c3 foundation Cure Rare Disease.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was reviewed and approved by the UMass Chan Medical School Institutional Review Board (IRB), Institutional Biosafety Committee, and Center for IRB Intelligence (CIRBI). External safety oversight was provided by an independent data safety monitor. The study was approved by the Food and Drug Administration (IND 28497). Families gave written informed consent for the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors